Non-Small-Cell Lung Cancer – Unmet Need – Detailed, Expanded Analysis: Metastatic Squamous Non-Small-Cell Lung Cancer (US/EU)

With only a small percentage of patients harboring a biomarker-driven metastatic squamous non-small-cell lung cancer (NSCLC) (about 10% of all patients in the G7 countries), the preferred first-line approach centers on immune checkpoint inhibitors. As such, physicians have a limited array of treatment options; of these options, Keytruda (Merck & Co.) and Libtayo (Regeneron Pharmaceuticals)—either alone or with a platinum doublet—are the most prescribed (nearly 50% of all patients in the G7 countries). Substantial unmet need remains in the treatment of metastatic squamous NSCLC, particularly in terms of extending patients’ overall survival and reducing treatments’ toxicity.

Questions answered

  • What are the current areas of unmet need and potential opportunity in the treatment of metastatic squamous NSCLC?
  • How do existing therapies, particularly immune checkpoint inhibitors, measure up to key treatment drivers and goals for this patient subpopulation?
  • What key factors drive treatment decisions and define the goals for managing metastatic squamous NSCLC?
  • In the context of a hypothetical new first-line treatment for metastatic squamous NSCLC, what trade-offs across diverse clinical attributes and pricing are deemed acceptable by surveyed medical oncologists?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in March 2024

Key drugs: Keytruda, Libtayo, Tecentriq, Opdivo, and Yervoy

Product description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Key feature

The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.

launch Related Market Assessment Reports